Citigroup and RBC issued rating updates and price targets for Bio-Techne on June 6, 2026, which is listed on the Nasdaq stock exchange.
3 reports, 1 independent
Updated Aug 16
Gone quiet
- Reports
- 3
- Developments
- 1
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Citigroup and RBC issued rating updates and price targets for Bio-Techne on June 6, 2026, which is listed on the Nasdaq stock exchange.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Bio-Techne
company
Nothing else this week.
-
Citigroup
American investment bank and financial services corporation
Related events
- Bank of America updated its price objective and rating, while Citigroup reissued a neutral rating on Biogen shares.
- Citigroup upped its price objective and gave a 'buy' rating, while Royal Bank of Canada reissued an 'outperform' rating for Abbott Laboratories.
- RBC and Citigroup boosted price objectives on Lockheed Martin shares, with MarketBeat aggregating the analyst ratings.
- Citigroup maintained a market outperform rating for Ethos Technologies Inc. on November 6, 2026.
- Citigroup and Jefferies Financial Group raised their price targets and issued buy ratings for Beauty.